Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NYSE:NVS
- CUSIP: N/A
- Web: www.novartis.com
Capitalization:- Market Cap: $192.44 billion
- Outstanding Shares: 2,365,595,000
Average Prices:- 50 Day Moving Avg: $77.11
- 200 Day Moving Avg: $74.07
- 52 Week Range: $66.93 - $83.58
P/E:- Trailing P/E Ratio: 30.58
- Foreward P/E Ratio: 15.67
- P/E Growth: 3.12
Sales & Book Value:- Annual Revenue: $49.36 billion
- Price / Sales: 3.90
- Book Value: $28.57 per share
- Price / Book: 2.85
Dividend:- Annual Dividend: $2.30
- Dividend Yield: 3.3%
Profitability:- EBIDTA: $14.34 billion
- Net Margins: 13.80%
- Return on Equity: 15.37%
- Return on Assets: 8.57%
Debt:- Debt-to-Equity Ratio: 0.24%
- Current Ratio: 1.12%
- Quick Ratio: 0.84%
Misc:- Average Volume: 2.61 million shs.
- Beta: 0.73
- Short Ratio: 1.36
Frequently Asked Questions for Novartis AG (NYSE:NVS)
What is Novartis AG's stock symbol?
Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?
Novartis AG declared an annual dividend on Friday, January 27th. Investors of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis AG's Dividend History.
How will Novartis AG's stock buyback program work?
Novartis AG declared that its board has approved a stock repurchase program on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued.
How were Novartis AG's earnings last quarter?
Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, April, 25th. The company reported $1.13 EPS for the quarter, beating the Zacks' consensus estimate of $1.10 by $0.03. The business had revenue of $11.54 billion for the quarter, compared to analyst estimates of $11.59 billion. Novartis AG had a net margin of 13.80% and a return on equity of 15.37%. The business's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the business posted $1.17 EPS. View Novartis AG's Earnings History.
Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?
14 analysts have issued twelve-month price targets for Novartis AG's stock. Their forecasts range from $74.37 to $92.00. On average, they anticipate Novartis AG's share price to reach $82.09 in the next year. View Analyst Ratings for Novartis AG.
Who are some of Novartis AG's key competitors?
Some companies that are related to Novartis AG include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co. (MRK), Sanofi SA (SNY), AbbVie (ABBV), GlaxoSmithKline plc (GSK), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Eli Lilly and Co (LLY), Shire PLC (SHPG), GW Pharmaceuticals PLC- (GWPH), Aerie Pharmaceuticals (AERI), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Retrophin (RTRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI) and Zogenix (ZGNX).
Who owns Novartis AG stock?
Novartis AG's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (0.92%), Wells Fargo & Company MN (0.38%), Parnassus Investments CA (0.35%), Bank of America Corp DE (0.31%), Loomis Sayles & Co. L P (0.26%) and Fisher Asset Management LLC (0.26%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.
Who sold Novartis AG stock? Who is selling Novartis AG stock?
Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, JPMorgan Chase & Co., Ameriprise Financial Inc., Lazard Asset Management LLC, United States Steel & Carnegie Pension Fund, Advisors Capital Management LLC, State Street Corp and PNC Financial Services Group Inc.. View Insider Buying and Selling for Novartis AG.
Who bought Novartis AG stock? Who is buying Novartis AG stock?
Novartis AG's stock was acquired by a variety of institutional investors in the last quarter, including Parnassus Investments CA, BlackRock Inc., Janus Capital Management LLC, Wells Fargo & Company MN, Karp Capital Management Corp, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Point72 Asset Management L.P.. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.
How do I buy Novartis AG stock?
Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Novartis AG stock cost?
One share of Novartis AG stock can currently be purchased for approximately $81.35.
Earnings History for Novartis AG (NYSE:NVS)Earnings History by Quarter for Novartis AG (NYSE:NVS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/25/2017 | 3/31/2017 | $1.10 | $1.13 | $11.59 billion | $11.54 billion | View | N/A |  |
| 1/25/2017 | Q416 | $1.12 | $1.12 | $12.44 billion | $12.32 billion | View | N/A | |
| 10/25/2016 | Q316 | $1.19 | $1.23 | $12.24 billion | $12.13 billion | View | Listen | |
| 7/19/2016 | Q216 | $1.18 | $1.23 | $12.33 billion | $12.47 billion | View | Listen | |
| 4/21/2016 | Q116 | $1.18 | $1.17 | $11.90 billion | $11.60 billion | View | Listen | |
| 1/27/2016 | Q415 | $1.18 | $1.14 | $12.64 billion | $12.52 billion | View | Listen | |
| 10/27/2015 | Q315 | $1.31 | $1.27 | $12.66 billion | $12.30 billion | View | Listen | |
| 7/21/2015 | Q215 | $1.20 | $1.27 | $12.45 billion | $12.70 billion | View | Listen | |
| 4/23/2015 | Q115 | $1.12 | $1.33 | $12.90 million | $11.94 billion | View | N/A | |
| 1/27/2015 | Q314 | $1.13 | $1.21 | $14.68 billion | $14.63 billion | View | N/A | |
| 7/17/2014 | Q214 | $1.36 | $1.36 | $14.83 billion | $14.64 billion | View | N/A | |
| 4/24/2014 | Q1 2014 | $1.33 | $1.31 | $14.25 billion | $14.02 billion | View | N/A | |
| 1/29/2014 | Q413 | $1.27 | $1.20 | $15.16 billion | $15.08 billion | View | N/A | |
| 10/22/2013 | Q313 | $1.31 | $1.26 | $14.28 billion | $14.34 billion | View | N/A | |
| 7/17/2013 | Q213 | $1.29 | $1.30 | $14.39 billion | $14.50 billion | View | N/A | |
| 4/24/2013 | Q113 | $1.28 | $1.32 | $14.02 million | $14.02 billion | View | N/A | |
| 1/23/2013 | Q412 | $1.19 | $1.27 | $14.42 billion | $14.80 billion | View | N/A | |
| 10/25/2012 | | $1.34 | $1.34 | | | View | N/A | |
| 7/19/2012 | | $1.33 | $1.38 | | | View | N/A | |
| 4/24/2012 | | $1.30 | $1.27 | | | View | N/A | |
| 1/25/2012 | | $1.26 | $1.23 | | | View | N/A | |
| 10/25/2011 | | $1.45 | $1.45 | | | View | N/A | |
| 7/19/2011 | | $1.46 | $1.48 | | | View | N/A | |
| 4/19/2011 | | $1.30 | $1.41 | | | View | N/A | |
| 1/27/2011 | | $1.25 | $1.14 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Novartis AG (NYSE:NVS)2017 EPS Consensus Estimate: $4.88
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $1.08 | $1.15 | $1.12 |
| Q2 2017 | 1 | $1.22 | $1.22 | $1.22 |
| Q3 2017 | 1 | $1.25 | $1.25 | $1.25 |
| Q4 2017 | 1 | $1.29 | $1.29 | $1.29 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Novartis AG (NYSE:NVS)| Most Recent Dividend: | 3/3/2017 |
| Annual Dividend: | $2.30 |
| Dividend Yield: | 2.83% |
| Dividend Growth: | 3.90% (3 Year Average) |
| Payout Ratio: | 82.14% (Trailing 12 Months of Earnings)
48.73% (Based on This Year's Estimates)
44.32% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Novartis AG (NYSE:NVS)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/27/2017 | Annual | $2.33 | | 3/1/2017 | 3/3/2017 | 3/3/2017 |
| 2/1/2016 | Annual | $2.34 | | 2/24/2016 | 2/26/2016 | 2/26/2016 |
| 2/4/2014 | annual | $2.72 | 3.48% | 2/27/2014 | 3/3/2014 | 3/11/2014 |
| 2/11/2013 | annual | $2.53 | 3.71% | 2/26/2013 | 2/28/2013 | 4/5/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.82%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/11/2016 | Institutes For Biomed Novartis | Major Shareholder | Buy | 277,777 | $18.00 | $4,999,986.00 | |
| 2/17/2016 | Bioventures Ltd Novartis | Major Shareholder | Buy | 375,000 | $8.00 | $3,000,000.00 | |
| 9/22/2014 | Bioventures Ltd Novartis | Major Shareholder | Buy | 325,000 | $15.00 | $4,875,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
| Source: |
|
| Date | Headline |
|---|
 | Cambridge largely spared as Novartis cuts hundreds of jobs
finance.yahoo.com - May 24 at 7:07 PM |
| The Current State Of The Breast Cancer Treatment Space
finance.yahoo.com - May 23 at 6:26 PM |
| Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion
finance.yahoo.com - May 23 at 10:06 AM |
 | Novartis set for 39 data presentations at ASCO - Seeking Alpha
seekingalpha.com - May 20 at 11:33 PM |
| Novartis to cut around 500 jobs in Switzerland, add 350
finance.yahoo.com - May 19 at 7:29 PM |
| Novartis: Follow The (Belgian) Yellow Brick Road - Seeking Alpha
seekingalpha.com - May 19 at 11:43 AM |
| Novartis set for 15 data presentations at ASCO - Seeking Alpha
seekingalpha.com - May 19 at 11:43 AM |
| CHMP backs Novartis's Zykadia for first-line use in lung cancer
finance.yahoo.com - May 19 at 11:43 AM |
| Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
finance.yahoo.com - May 19 at 11:43 AM |
| Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis
finance.yahoo.com - May 16 at 10:09 AM |
 | Novartis AG (NVS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 15 at 2:46 PM |
| GlaxoSmithKline Could Buy Out Partner Novartis
finance.yahoo.com - May 15 at 10:06 AM |
| What Is Sparking Novartis Shares This Spring? - Seeking Alpha
seekingalpha.com - May 12 at 12:27 AM |
| [$$] Novartis Has the Right Prescription for Profits
finance.yahoo.com - May 6 at 8:42 AM |
| Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan
finance.yahoo.com - May 5 at 9:02 AM |
| Somewhat Favorable Media Coverage Likely to Impact Novartis AG (NVS) Stock Price
www.americanbankingnews.com - May 4 at 10:00 PM |
| Novartis, Roche back French gene therapy start-up Vivet
finance.yahoo.com - May 4 at 7:05 PM |
| Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss
finance.yahoo.com - May 4 at 7:05 PM |
 | Greatmark Investment Partners, Inc. Buys Novartis AG, Chesapeake Energy Corp, Coherent Inc, ...
www.nasdaq.com - May 3 at 8:07 PM |
| Stem cell biotech Magenta bags $50M, strikes licensing deal with Novartis
finance.yahoo.com - May 2 at 11:19 AM |
| How GlaxoSmithKline’s Vaccines Business Performed in 1Q17
finance.yahoo.com - May 2 at 11:19 AM |
| Cambridge's bluebird bio licenses delivery tech to Novartis, GSK
finance.yahoo.com - May 2 at 11:19 AM |
| ETFs with exposure to Novartis AG : May 1, 2017
finance.yahoo.com - May 1 at 5:52 PM |
| Novartis AG (NVS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 1 at 5:22 PM |
| Novartis AG (NVS) Receives Daily Coverage Optimism Rating of 0.28
www.americanbankingnews.com - May 1 at 3:32 PM |
| Novartis’s Valuation after 1Q17 Earnings
finance.yahoo.com - May 1 at 12:09 PM |
| How GlaxoSmithKline’s Business Segments Performed in 1Q17
finance.yahoo.com - May 1 at 12:09 PM |
| Novartis AG (NVS) to Post FY2017 Earnings of $4.71 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 1 at 9:46 AM |
| How Far Into the Drug Pipeline Should the FTC Reach?
finance.yahoo.com - April 30 at 8:10 PM |
| Research Analysts Set Expectations for Novartis AG's FY2020 Earnings (NVS)
www.americanbankingnews.com - April 29 at 12:46 AM |
| 1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business
finance.yahoo.com - April 28 at 7:56 PM |
| Novartis’s 1Q17 Earnings: Recent Developments
finance.yahoo.com - April 28 at 7:56 PM |
| Novartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
finance.yahoo.com - April 28 at 7:56 PM |
| U.S. FDA approves Novartis' leukemia treatment
finance.yahoo.com - April 28 at 7:56 PM |
| Novartis AG (NVS) Receiving Somewhat Negative News Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 2:51 PM |
| 1Q17 Earnings for Novartis’s Sandoz, Its Generics Business
finance.yahoo.com - April 28 at 8:45 AM |
| Jerome Dodson Comments on Novartis
finance.yahoo.com - April 27 at 7:25 PM |
| Why Novartis’s 1Q17 Revenues Missed Analysts’ Estimates
finance.yahoo.com - April 27 at 7:25 PM |
| Novartis’s 1Q17 Earnings: Segment Performances
finance.yahoo.com - April 27 at 7:25 PM |
| Novartis’s 1Q17 Earnings: Innovative Medicines Segment
finance.yahoo.com - April 27 at 7:25 PM |
| Earnings Reaction History: Novartis AG, 42.9% Follow-Through Indicator, 1.2% Sensitive - Nasdaq
www.nasdaq.com - April 26 at 11:21 PM |
| Novartis AG (NVS) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 6:19 PM |
| GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business
finance.yahoo.com - April 26 at 6:19 PM |
| Glaxo (GSK) Beats Earnings and Revenues in Q1
finance.yahoo.com - April 26 at 6:19 PM |
| Vetr Inc. Downgrades Novartis AG (NVS) to Hold
www.americanbankingnews.com - April 26 at 12:14 AM |
 | Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders
www.bizjournals.com - April 25 at 6:09 PM |
 | Novartis Q1 Core Profit Tops Estimates; Backs; Backs FY17 View; Shares Up
www.rttnews.com - April 25 at 6:09 PM |
| Novartis Q1 Profit Down On Weak Sales; Backs FY17 View - Quick Facts
www.nasdaq.com - April 25 at 6:09 PM |
| Swiss drugs giant Novartis posts 15 percent drop in profit
finance.yahoo.com - April 25 at 6:09 PM |
| Novartis to speed up bid for MS drug approval, changes target
finance.yahoo.com - April 25 at 6:09 PM |
Novartis AG (NVS) Chart for Friday, May, 26, 2017
